Background Sacubitril/valsartan improves outcome in patients with heart failure (HF) with
reduced left ventricular (LV) ejection fraction (EF, HFrEF). However, little is known about …

Background Sacubitril/valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure (HF) with reduced ejection fraction (HFrEF) …

Objective: We evaluated the clinical efficacy of sacubitril/valsartan in a group of ambulatory
patients with heart failure (HF) with reduced ejection fraction (HFrEF) referred to our HF …

Abstract Introduction Sacubitril/valsartan (S–V) has been shown to reduce clinical outcomes
in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been …

The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Background The effects of sacubitril/valsartan in patients with chronic heart failure with
reduced ejection fraction (HFrEF) were recently reported. However, the hemodynamic …

Background: Sacubitril/Valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). The …

Aim Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure
and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and …

Heart failure (HF) represents a widespread health problem characterized by high morbidity
and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients …

Background Observational studies have demonstrated that treatment with
sacubitril/valsartan may improve left ventricular (LV) systolic and diastolic function in …